NovoCure Limited reported earnings of -$ 0.09 per NVCR share on Oct 29, 2026, falling short of analysts' expectations by
| Report Date | Oct 29, 2026 |
|---|---|
| Forecasted EPS | -$ 0.23 |
| Earnings Per Share (Surprise) | -$ 0.09 (+$ 0.1449) |
| Last Year's EPS | -$ 0.31 |
| EPS YoY Change |
Out of the last 51 earnings reporting periods, NovoCure Limited beat analysts’ expectations 25 times and fell short of expectations 17 time(s). NovoCure Limited reported earnings per share of -$ 0.09 in the last report surpassing an estimated EPS of -$ 0.23 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Oct 29, 2026 | -$ 0.23 | -$ 0.09 | -$ 0.33 | |
| Jul 23, 2026 | -$ 0.33 | -$ 0.13 | -$ 0.36 | |
| Apr 30, 2026 | -$ 0.51 | -$ 0.62 | -$ 0.31 | |
| Feb 26, 2026 | -$ 0.41 | -$ 0.22 | -$ 0.61 | |
| Oct 30, 2025 | -$ 0.42 | -$ 0.33 | -$ 0.28 | |
| Jul 24, 2025 | -$ 0.39 | -$ 0.36 | -$ 0.31 | |
| Apr 24, 2025 | -$ 0.47 | -$ 0.31 | -$ 0.36 | |
| Feb 27, 2025 | -$ 0.34 | -$ 0.61 | -$ 0.45 | |
| Oct 30, 2024 | -$ 0.34 | -$ 0.28 | -$ 0.46 | |
| Jul 25, 2024 | -$ 0.40 | -$ 0.31 | -$ 0.54 | |
| May 2, 2024 | -$ 0.43 | -$ 0.36 | -$ 0.50 | |
| Feb 22, 2024 | -$ 0.53 | -$ 0.45 | -$ 0.36 | |
| Oct 26, 2023 | -$ 0.52 | -$ 0.46 | -$ 0.25 | |
| Jul 27, 2023 | -$ 0.50 | -$ 0.54 | -$ 0.23 | |
| May 4, 2023 | -$ 0.36 | -$ 0.50 | -$ 0.04 | |
| Feb 23, 2023 | -$ 0.32 | -$ 0.36 | -$ 0.25 | |
| Oct 27, 2022 | -$ 0.30 | -$ 0.25 | -$ 0.13 | |
| Jul 28, 2022 | -$ 0.14 | -$ 0.23 | -$ 0.14 | |
| Apr 28, 2022 | -$ 0.17 | -$ 0.04 | -$ 0.04 | |
| Feb 24, 2022 | -$ 0.10 | -$ 0.25 | $ 0.04 |
NovoCure Limited’s stock was trading at $ 14.17 on Oct 28, 2026 a day before the last earnings report was released.Following the release of the earnings report, NVCR’s price decreased to $ 13.15 on Oct 30, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Oct 29, 2026 | -$ 0.09 | $ 14.17 | $ 13.15 | |
| Jul 23, 2026 | -$ 0.13 | $ 15.57 | $ 17.65 | |
| Apr 30, 2026 | -$ 0.62 | $ 11.93 | $ 16.62 | |
| Feb 26, 2026 | -$ 0.22 | $ 14.99 | $ 13.67 | |
| Oct 30, 2025 | -$ 0.33 | $ 13.48 | $ 12.81 | |
| Jul 24, 2025 | -$ 0.36 | $ 16.51 | $ 12.04 | |
| Apr 24, 2025 | -$ 0.31 | $ 17.77 | $ 18.50 | |
| Feb 27, 2025 | -$ 0.61 | $ 21.96 | $ 19.07 | |
| Oct 30, 2024 | -$ 0.28 | $ 16.89 | $ 15.18 | |
| Jul 25, 2024 | -$ 0.31 | $ 18.79 | $ 19.02 | |
| May 2, 2024 | -$ 0.36 | $ 12.74 | $ 14.78 | |
| Feb 22, 2024 | -$ 0.45 | $ 15.62 | $ 15.22 | |
| Oct 26, 2023 | -$ 0.46 | $ 14.08 | $ 12.64 | |
| Jul 27, 2023 | -$ 0.54 | $ 40.34 | $ 33.32 | |
| May 4, 2023 | -$ 0.50 | $ 65.94 | $ 68.23 | |
| Feb 23, 2023 | -$ 0.36 | $ 82.01 | $ 76.98 | |
| Oct 27, 2022 | -$ 0.25 | $ 67.71 | $ 70.06 | |
| Jul 28, 2022 | -$ 0.23 | $ 73.96 | $ 67.99 | |
| Apr 28, 2022 | -$ 0.04 | $ 76.95 | $ 76.58 | |
| Feb 24, 2022 | -$ 0.25 | $ 72.96 | $ 80.33 |
NovoCure Limited released its most recent earnings reports in October 2026, July 2026, April 2026, February 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
NovoCure Limited beat analysts’ expectations during the last earnings period by
